Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Joerger, M; Baty, F; Früh, M; Droege, C; Stahel, R A; Betticher, D C; von Moos, R; Ochsenbein, A; Pless, M; Gautschi, O; Rothschild, S; Brauchli, P; Klingbiel, D; Zappa, F; Brutsche, M (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer, 85(2):306-313.

Frauenfelder, T; Puhan, Milo A; Lazor, R; von Garnier, C; Bremerich, J; Niemann, T; Christe, A; Montet, X; Gautschi, O; Weder, W; Kohler, M (2014). Early detection of lung cancer: A statement from an expert panel of the Swiss university hospitals on lung cancer screening. Respiration, 87(3):254-264.

Zappa, F; Droege, C; Betticher, D; von Moos, R; Bubendorf, L; Ochsenbein, A; Gautschi, O; Oppliger Leibundgut, E; Froesch, P; Stahel, R; Hess, T; Rauch, D; Schmid, P; Mayer, M; Crowe, S; Brauchli, P; Ribi, K; Pless, M (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3):239-244.

Weber, A; Zimmermann, D R; Moch, H (2010). KRAS-Mutationsstatus und kolorektales Karzinom - Diagnostik. In: Köberle, D; Gautschi, O. KRAS-Mutationsstatus und kolorektales Karzinom. Bremen: UNI-MED Science, UNI-MED Verlag AG, 29-33.

Cadosch, D; Sutanto, M; Chan, E; Mhawi, A; Gautschi, O; von Katterfeld, B; Simmen, H P; Filgueira, L (2009). Titanium uptake, induction of RANK-L expression, and enhanced proliferation of human T-lymphocytes. Journal of Orthopaedic Research, 28(3):341 -347.

This list was generated on Fri Sep 22 01:53:53 2017 CEST.